OncoZenge AB

Corporate Details

ISIN(s):

SE0015504097

LEI:

2549003980RBCR6NIF38

Country:

Sweden

Address:

Gustavslundsvagen 34, 5 tr, 167 51 Bromma

Website:

https://oncozenge.se/

Sector:

Professional, scientific and technical activities

Industry:

Research and experimental development on natural sciences and engineering

Description

OncoZenge AB is a pharmaceutical company focused on developing innovative treatments for oral pain. Its lead candidate, BupiZenge™, is a novel lozenge formulation that utilizes the well-established local anesthetic bupivacaine to provide targeted, non-opioid pain relief. The primary indication is oral mucositis, a debilitating side effect of cancer radiotherapy and chemotherapy that represents a significant unmet medical need. By alleviating pain locally, BupiZenge™ aims to improve patients' quality of life, reduce the need for systemic opioids, and prevent hospitalizations. Having successfully completed Phase 1 and 2 trials and received regulatory guidance from the EMA and FDA, the company is preparing for Phase 3 studies and establishing commercial partnerships for market entry. The treatment also has potential applications for other oral pain conditions.